TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)


Total Award Amount

  • 70738.00
  • Direct Costs

  • 56142.00
  • Sponsor Award Id

  • Contributor

  • Erica Stringer-Reasor M.D.   Investigator  
  • Lisle Nabell M.D.   Investigator